GlassScriptPhysician profile
Weiqiang Gao
NPI 1447570304
$17,695.77
in general payments reported to CMS, 2019-2025
18 companies · $4,436 in 2025
The $4,436 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2021: $136 · 2022: $4,420 · 2023: $3,370 · 2024: $5,023 · 2025: $4,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $1,412 · Travel and Lodging: $37.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,380.00 |
| Food and Beverage | $1,412.03 |
| Travel and Lodging | $37.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,420.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $4,350.00 | 2024-2025 | Tagrisso, Imfinzi, Lynparza |
| Genzyme Corporation | $3,661.55 | 2024 | |
| Karyopharm Therapeutics INC. | $3,260.00 | 2023 | Xpovio |
| Lilly USA, LLC | $611.58 | 2019-2025 | Verzenio |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Abbvie INC. | $202.60 | 2024-2025 | |
| Sobi, INC | $200.00 | 2024 | |
| Beone Medicines USA, INC. | $137.03 | 2025 | Tevimbra |
| Genentech, INC. | $132.13 | 2025 | Itovebi |
| Stemline Therapeutics INC. | $125.29 | 2025 | Orserdu |
| Puma Biotechnology, INC. | $122.83 | 2019 | |
| Tempus Ai, INC | $74.72 | 2025 | Xt Cdx |
| Janssen Biotech, INC. | $42.83 | 2025 | Tecvayli, Darzalex |
| Pfizer INC. | $38.99 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $14.75 | 2019 | |
| Celgene Corporation | $14.55 | 2025 | Reblozyl |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Weiqiang Gao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.